In case of heart failure or a decrease in LVEF of 20% or more from baseline that is below the lower limit of normal, therapy with BRAF inhibitors should be stopped and, in the event of recovery, resumed at the same dosage, while therapy with MEK inhibitors should be permanently discontinued.43 Initiation of treatment with BRAF inhibitors is not recommended in patients with QTc of more than 500 milliseconds, and BRAF inhibitors should be stopped at a QTc of more than 500 milliseconds or at an increase in QTc of more than 60 milliseconds from baseline values at any time during the treatment. The gene discussed is BRAF; the disease is heart failure.